Sangamo Therapeutics Stock Plunges

Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership
The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator.
Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact
Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer Inc. terminated a hemophilia A gene-therapy partnership.
Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact
Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.
Sangamo spirals after Pfizer halts hemophilia A gene therapy partnership
The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future of gene therapies.
Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal
Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development agreement, sending its shares down nearly 64% in extended trade. Sangamo added that it has now regained the rights to the therapy's development and would explore all options to advance the program,
Pfizer kills hemophilia gene therapy deal, imperiling Sangamo
Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.
Why did Pfizer's exit from gene therapy program hit Sangamo hard?
Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the reasons for the selloff.
Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership
Sangamo Therapeutics' (SGMO) shares were sinking intraday Tuesday after the company said its partner Pfizer (PFE) decided not to proceed with further development of a new gene therapy to treat hemophilia A,
FierceBiotech1d
Pfizer cuts losses on near-approval hemophilia gene therapy, adding to troubled Sangamo's woes
Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...
Lost Money on Sangamo Therapeutics, Inc. (SGMO)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
Benzinga.com3d
9 Analysts Have This To Say About Sangamo Therapeutics
9 analysts have shared their evaluations of Sangamo Therapeutics SGMO during the recent three months, expressing a mix of ...
Business Wire1d
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities ...
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of S ...
Sangamo Therapeutics: Left At The Alter (Rating Downgrade)
Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...
BioPharma Dive1d
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...
Options run thin for Sangamo Therapeutics after Pfizer deal crashes
Abrupt end of Pfizer's hemophilia A gene therapy deal with Sangamo is the latest in a line of flip-flops between the big drug ...
Sangamo to regain rights to giroctocogene fitelparvovec from Pfizer
Sangamo (SGMO) announced it will regain development and commercialization rights to giroctocogene fitelparvovec, an investigational gene ...